Short answer
ROCKET PHARMACEUTICALS, INC. (RCKT) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$49M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$49M
- +2.2% YoY · −140.0% QoQ
- EPS (diluted)
- −$0.43
- +4.4% YoY · −139.8% QoQ
Source: XBRL data from the ROCKET PHARMACEUTICALS, INC. (RCKT) Q3 2026 10-Q on SEC EDGAR. USD.
ROCKET PHARMACEUTICALS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales; KRESLADI™ not expected to generate near-term material revenue
- Operating loss $51.0M vs $52.2M YoY; operating margin not applicable with zero revenue
- Danon R&D $6.2M vs $5.6M YoY, strongest program investment; RP-A601 R&D $1.0M vs $1.5M
- Cash, equivalents and investments $279.4M at September 30; operating cash use $124.1M nine-month
- Hercules financing provided $35M initial draw; runway projected into third quarter 2028, with additional borrowing potentially extending to 2029
Risk Factors
- New secured debt risk: September 30, 2026 Loan Agreement provides up to $150.0 million, secured by substantially all assets
- Regulatory and covenant risk: RP-A501 clinical hold or discontinuation raises qualified-cash requirement to 75% of outstanding principal
- Operational flexibility risk: Loan covenants restrict financing, acquisitions, asset licensing, and strategic transactions
- Interest-rate risk: Term Loans bear floating interest at the greater of 9.15% or prime rate plus 2.40%
- Liquidity risk: $50.0 million final tranche requires lenders’ investment committee approval in its sole discretion
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ROCKET PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.